ATE481405T1 - Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors - Google Patents

Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors

Info

Publication number
ATE481405T1
ATE481405T1 AT07842582T AT07842582T ATE481405T1 AT E481405 T1 ATE481405 T1 AT E481405T1 AT 07842582 T AT07842582 T AT 07842582T AT 07842582 T AT07842582 T AT 07842582T AT E481405 T1 ATE481405 T1 AT E481405T1
Authority
AT
Austria
Prior art keywords
thiazolpyrazolopyrimidines
antagonists
crf1 receptor
crf1
receptor
Prior art date
Application number
AT07842582T
Other languages
German (de)
English (en)
Inventor
Zhaogen Chen
Chafiq Hamdouchi
Erik Hembre
Philip Hipskind
Jason Myers
Takako Takakuwa
James Toth
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38924802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE481405(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE481405T1 publication Critical patent/ATE481405T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT07842582T 2006-09-20 2007-09-17 Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors ATE481405T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82626406P 2006-09-20 2006-09-20
PCT/US2007/078605 WO2008036579A1 (en) 2006-09-20 2007-09-17 Thiazole pyrazolopyrimidines as crf1 receptor antagonists

Publications (1)

Publication Number Publication Date
ATE481405T1 true ATE481405T1 (de) 2010-10-15

Family

ID=38924802

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07842582T ATE481405T1 (de) 2006-09-20 2007-09-17 Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors

Country Status (33)

Country Link
US (1) US8030304B2 (enExample)
EP (1) EP2094709B1 (enExample)
JP (1) JP5161226B2 (enExample)
KR (1) KR101088239B1 (enExample)
CN (1) CN101516887B (enExample)
AR (1) AR062886A1 (enExample)
AT (1) ATE481405T1 (enExample)
AU (1) AU2007297421B2 (enExample)
BR (1) BRPI0717023B8 (enExample)
CA (1) CA2663511C (enExample)
CL (1) CL2007002693A1 (enExample)
CR (1) CR10682A (enExample)
CY (1) CY1110854T1 (enExample)
DE (1) DE602007009305D1 (enExample)
DK (1) DK2094709T3 (enExample)
EA (1) EA015179B1 (enExample)
ES (1) ES2350282T3 (enExample)
HR (1) HRP20100516T1 (enExample)
IL (1) IL197614A (enExample)
MA (1) MA30798B1 (enExample)
MX (1) MX2009003125A (enExample)
MY (1) MY146388A (enExample)
NO (1) NO20091489L (enExample)
NZ (1) NZ575572A (enExample)
PE (1) PE20081377A1 (enExample)
PL (1) PL2094709T3 (enExample)
PT (1) PT2094709E (enExample)
RS (1) RS51545B (enExample)
SI (1) SI2094709T1 (enExample)
TN (1) TN2009000095A1 (enExample)
TW (1) TWI402269B (enExample)
UA (1) UA96458C2 (enExample)
WO (1) WO2008036579A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PT2350079E (pt) 2008-10-02 2012-12-20 Lilly Co Eli Compostos tiazolil-pirazolopirimidina como intermediários de síntese e processos de síntese relacionados
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
LT3096756T (lt) * 2014-01-21 2024-08-26 Neurocrine Biosciences, Inc. Crf1 receptoriaus antagonistai, skirti įgimtos antinksčių hiperplazijos gydymui
PL236355B1 (pl) * 2015-04-02 2021-01-11 Celon Pharma Spolka Akcyjna Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
CA3039026A1 (en) 2016-09-07 2018-03-15 The Regents Of The University Of California Allosteric corticotropin-releasing factor receptor 1 (crfr1) antagonists that decrease p-tau and improve cognition
KR102644781B1 (ko) * 2017-08-14 2024-03-06 스프루스 바이오사이언시스 인코포레이티드 코티코트로핀 방출 인자 수용체 길항제
BR112020002967A2 (pt) 2017-08-14 2020-08-11 Spruce Biosciences, Inc. antagonistas de receptor de fator de liberação de corticotropina
BR112020024062A2 (pt) * 2018-04-27 2021-02-09 Spruce Biosciences, Inc. métodos para o tratamento de tumores de restos adrenais de testículo e de ovário
CN109134481B (zh) * 2018-08-07 2021-05-14 中山大学 一种取代吡咯色原酮类化合物或其药学上可接受的盐及其制备方法和应用
TWI714231B (zh) * 2018-09-04 2020-12-21 美商美國禮來大藥廠 2,6-二胺基吡啶化合物
FI3984523T3 (fi) 2018-12-07 2025-10-21 Neurocrine Biosciences Inc Crf1-reseptorin antagonisti, lääkeformulaatioita ja niiden kiinteitä muotoja synnynnäisen lisämunuaisten liikakasvun hoitoon
AU2020318970A1 (en) * 2019-07-19 2022-03-03 Spruce Biosciences, Inc. Methods of treating congenital adrenal hyperplasia
CA3152590A1 (en) 2019-09-27 2021-04-01 Evan Smith Crf receptor antagonists and methods of use
WO2021113263A1 (en) * 2019-12-04 2021-06-10 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
GR1010096B (el) * 2020-07-02 2021-10-08 Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε, Πυραζολο[1,5-a]πυριμιδινες με δραση αναστολης της αυτοταξινης
KR20230043222A (ko) * 2020-08-12 2023-03-30 스프루스 바이오사이언시스 인코포레이티드 다낭성 난소 증후군을 치료하기 위한 방법 및 조성물
US20240024330A1 (en) 2020-08-26 2024-01-25 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
JP2024510260A (ja) 2021-03-19 2024-03-06 クリネティックス ファーマシューティカルズ，インク． 疾患の治療のためのメラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニスト
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof
WO2023091684A1 (en) * 2021-11-19 2023-05-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof
WO2023163945A1 (en) * 2022-02-23 2023-08-31 Crinetics Pharmaceuticals, Inc. Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome
WO2025188842A1 (en) * 2024-03-08 2025-09-12 Spruce Biosciences, Inc. Amorphous solid dispersion of tildacerfont formulations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013676A1 (en) 1992-12-17 1994-06-23 Pfizer Inc. Pyrrolopyrimidines as crf antagonists
TR199800792T2 (xx) * 1996-02-07 1998-07-21 Janssen Pharmaceutica N.V. CRF resept�r antagonistleri olarak pirazolopirimidinler.
CZ299451B6 (cs) * 1996-07-24 2008-07-30 Bristol-Myers Squibb Pharma Company [1,5-a]-Pyrazolo-1,3,5- triaziny jejich použití afarmaceutické kompozice na jejich bázi
EP0915880B1 (en) 1996-07-24 2007-10-10 Bristol-Myers Squibb Pharma Company Azolo triazines and pyrimidines
DE69736711T2 (de) 1996-08-28 2007-09-20 Pfizer Inc. Substituierte 6,5-heterobicyclische-derivate
EP1040831A3 (en) * 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
AU4203500A (en) * 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
WO2001023388A2 (en) 1999-09-30 2001-04-05 Neurogen Corporation AMINO SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES
HRP20030822B1 (en) 2001-03-13 2008-01-31 Bristol-Myers Squibb Pharma Company 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands
CA2550948A1 (en) * 2003-12-22 2005-07-14 Sb Pharmco Puerto Rico Inc. Crf receptor antagonists and methods relating thereto

Also Published As

Publication number Publication date
BRPI0717023B8 (pt) 2021-05-25
KR20090052366A (ko) 2009-05-25
JP5161226B2 (ja) 2013-03-13
CA2663511A1 (en) 2008-03-27
AU2007297421B2 (en) 2012-03-08
EA015179B1 (ru) 2011-06-30
CL2007002693A1 (es) 2008-04-18
HRP20100516T1 (hr) 2010-10-31
MY146388A (en) 2012-08-15
RS51545B (sr) 2011-06-30
AU2007297421A1 (en) 2008-03-27
KR101088239B1 (ko) 2011-11-30
TW200821312A (en) 2008-05-16
UA96458C2 (ru) 2011-11-10
PL2094709T3 (pl) 2011-02-28
HK1132505A1 (en) 2010-02-26
WO2008036579A1 (en) 2008-03-27
CN101516887A (zh) 2009-08-26
US20100222339A1 (en) 2010-09-02
EP2094709A1 (en) 2009-09-02
PE20081377A1 (es) 2008-09-18
CR10682A (es) 2009-08-13
AR062886A1 (es) 2008-12-10
TWI402269B (zh) 2013-07-21
TN2009000095A1 (en) 2010-08-19
MA30798B1 (fr) 2009-10-01
CY1110854T1 (el) 2015-06-10
EP2094709B1 (en) 2010-09-15
BRPI0717023A2 (pt) 2014-03-11
NZ575572A (en) 2011-10-28
BRPI0717023B1 (pt) 2019-11-19
NO20091489L (no) 2009-04-16
ES2350282T3 (es) 2011-01-20
EA200970303A1 (ru) 2009-10-30
IL197614A0 (en) 2009-12-24
PT2094709E (pt) 2010-10-04
IL197614A (en) 2012-10-31
SI2094709T1 (sl) 2011-01-31
US8030304B2 (en) 2011-10-04
DE602007009305D1 (de) 2010-10-28
CN101516887B (zh) 2011-11-02
CA2663511C (en) 2012-12-04
JP2010504344A (ja) 2010-02-12
MX2009003125A (es) 2009-05-28
DK2094709T3 (da) 2010-12-06

Similar Documents

Publication Publication Date Title
ATE481405T1 (de) Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors
HRP20151108T1 (xx) Antagonisti nogo-receptora
EP2150115A4 (en) CYCLOPROPYLPYRROLIDINOREXIN Receptor Antagonists
ATE496051T1 (de) Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten
ATE505467T1 (de) 2-aza-bicycloä3.1.0ühexanderivate als orexin- rezeptorantagonisten
EP2004654A4 (en) Kinase Antagonists
ES2385606T8 (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
EP2049110A4 (en) BRAZED DIAZEPANOREXINE RECEPTOR ANTAGONISTS
BRPI0717937A2 (pt) Compostos de pirazona como antagonistas do receptor mineralocorticóide
EP2083864A4 (en) ANTAGONISTS OF PCSK9
EP2083859A4 (en) PCSK9 ANTAGONISTS
EP2083860A4 (en) PCSK9 ANTAGONISTS
ATE555111T1 (de) Chinuclidinol-derivate als muscarinrezeptor- antagonisten
DK2081951T3 (da) Progesteron-receptorantagonister
DK2009992T3 (da) Il-8 receptor-antagonister
ATE485270T1 (de) 2-phenylindole als antagonisten des prostaglandin-d2-rezeptors
EP2365749A4 (en) Quinolone NEURO PEPTIDE-S-Receptor Antagonists
ATE537149T1 (de) Sulfonyl-pyrazolinyl-1-carboxamidinderivate als 5-ht6-antagonisten
EP2254413A4 (en) IMIDAZOBENZAZEPIN-CGRP receptor antagonists
BRPI0817835A2 (pt) Antagonistas cgrp
ATE533744T1 (de) N-benzoypyrrolidin-3-ylamine als histamin-3 antagonisten
ATE517100T1 (de) Pyrrolidinarylether als nk3-rezeptorantagonisten
ATE519738T1 (de) Pyrrolidinarylether als nk3-rezeptorantagonisten
ATE421511T1 (de) Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors
ATE477243T1 (de) 2-aminochinoline als 5-ht(5a)- rezeptorantagonisten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2094709

Country of ref document: EP